Tocilizumab as first treatment option in optic neuropathy secondary to Graves’ orbitopathy
- 8 February 2018
- journal article
- case report
- Published by Taylor & Francis in Orbit
- Vol. 37 (6) , 450-453
Abstract
Dysthyroid optic neuropathy (DON) is one of the complications that can affect Graves’ orbitopathy (GO) patients. Its prevalence is estimated at less than 5%. It is usually treated with intravenous steroids, radiotherapy or orbital decompression. Tocilizumab has been proposed as a treatment option in cases of GO refractory to steroid treatment, with good clinical results. Our aim is to report the case of a patient with optic neuropathy secondary to GO treated with tocilizumab as primary treatment option.Keywords
This publication has 9 references indexed in Scilit:
- Complicanze chirurgiche in pazienti sottoposti a decompressione orbitaria per oftalmopatia di GravesActa Otorhinolaryngologica Italica, 2016
- Medical Treatment of Graves’ OrbitopathyHormone and Metabolic Research, 2015
- Compressive Optic Neuropathy and Repeat Orbital DecompressionOphthalmic Plastic & Reconstructive Surgery, 2015
- Acute Dysthyroid Optic Neuropathy Exacerbated by Orbital RadiotherapyOrbit, 2014
- Therapeutic Outcomes of High-Dose Intravenous Steroids in the Treatment of Dysthyroid Optic NeuropathyThyroid®, 2014
- Treatment of Active Corticosteroid-Resistant Graves’ OrbitopathyOphthalmic Plastic & Reconstructive Surgery, 2014
- Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid DiseasesPLOS ONE, 2010
- Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) surveyBritish Journal of Ophthalmology, 2006
- Optic Nerve Involvement in DysthyroidismOphthalmology, 1981